Moreover, gene alterations in FGF/FGF receptor (FGFR) have been reported after treatment with a CDK4/6 inhibitor and ET in patients with ER+ breast cancer, suggesting that FGF signaling mediates resistance to these therapies [13,14,15]. The gene discussed is CDK4; the disease is breast cancer.